文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > Comparative Anticoagulant and Platelet Modulatory Effects of Enoxaparin and Sulodexide
侵权投诉

Comparative Anticoagulant and Platelet Modulatory Effects of Enoxaparin and Sulodexide

ComparativeAnticoagulantandPlateletModulatoryEffectsofEnoxaparinandSulodexide

CaferAdiguzel,MD,OmerIqbal,MD,

DebraHoppensteadt,PhD,WalterJeske,PhD,

JosephineCunanan,MD,EvangelosLitinas,MD,HeZhu,MD,JeanineM.Walenga,PhD,andJawedFareed,PhD

Sulodexiderepresentsanovelantithromboticagentwithmultiplesitesofactiononbloodcoagulationandvascularprocesses.Thepurposeofthisstudywastocomparesulodexideandenoxaparinonanticoagulanteffects,tissuefactor(TF)-inducedactivationofplate-lets,inhibitionofmicroparticlegenerationandtoinvestigatetheireffectonheparin-inducedplateletaggregation(HIPA).Sulodexidewascomparedwithenoxaparinatequigravimetricconcentrations.Whencomparedtoenoxaparin,sulodexideproducedastron-geranticoagulanteffectintheprothrombintime(PT),activatedpartialthromboplastintime(APTT),Heptest,andthrombintime(TT)assays.Inaddition,sulodexidehadastrongerinhibitoryeffectonTF-mediatedmicroparticlegeneration(IC50¼2.8mg/mL),P-selectinexpression(IC50¼4.8mg/ml),andpla-teletaggregateformation(IC50¼8.5mg/mL)compared

andAppliedNumber5

501-511

#2009Author(s)tohigherIC50valueswithenoxaparin.Sulodexideandenoxaparinexhibitedasimilareffectonheparin-inducedthrombocytopenia(HIT)antibody-mediatedplateletactivationHIPAassays.Theseresultssuggestthatsulodexideisarelativelystrongeranticoagulantagentthanenoxaparin.Sulodexideissubcutaneouslyabsorbed.ItsabilitytoinhibitTF-mediatedplateletactivationmaycontributetotheobservedtherapeuticeffectsofsulodexideinmicrovascularvasculopathysuchasdiabeticnephropathy.Theseresultsalsosug-gestthatinhibitionofTFactivationofplateletsbysulo-dexidemaybeindependentofitsanticoagulanteffects.Theseresultswarrantfurtherinvestigationofsulodex-ideinadditionalpreclinicalandclinicalstudies.Keywords:sulodexide;enoxaparin;plateletmicropar-ticle;plateletactivation;plateletfactor4antibodies

Introduction

Thefirstlow-molecular-weightheparin(LMWH)wasintroducedforthetreatmentofvenousthrom-boembolism(VTE)morethan20yearsago.1Enoxa-parinisaLMWH,whichispreparedbythedepolymerizationofunfractionatedheparin(UFH).2ComparedwithUFH,LMWHsofferthe

FromtheDepartmentsofPathology(CA,OI,DH,JC,EL,JF)andPharmacology(DH,JF),andCardiovascularInstitute(WJ,JMW),LoyolaUniversityMedicalCenter,Maywood,IL.Addresscorrespondenceto:JawedFareed,DepartmentofPathol-ogyandPharmacology,LoyolaUniversityMedicalCenter,2160S.FirstAvenue,Maywood,IL60153;e-mail:jfareed@lumc.edu.convenienceofsubcutaneousadministrationandhavegreaterbioavailability(90%-100%),longerhalf-life(t1/2),amorepredictabledoseresponse,andapotentiallyimprovedsafetyprofile.3,4Low-molecular-weightheparinshavebeenshowntobeeffectiveandwell-toleratedalternativestoUFHintreatingandpreventingVTE.5-10EnoxaparinhasahigherratioofantifactorXatoantifactorIIaactivitythanUFH(4:1).11ThisisapotentialadvantageinthatfactorXagenerationoccursearlierinthecoagu-lationcascade,thusblockingasmallamountofXaresultinginpreventionofthegenerationoflargeramountsofthrombin.LaboratorymonitoringisnotgenerallyrequiredwithLMWHtherapy,exceptinpatientswithrenalinsufficiency.12

501

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email